Medartis (MED) Investor update summary

Strategic Focus and Market Positioning

• Pursuing a "From Head to Toe" strategy to become the global leader in hand, wrist, and broader orthopaedic solutions, with continued expansion in upper and lower extremities and a total addressable market of CHF 7.1bn.

• U.S. market share is growing, with a minimum 20% growth target for 2024 and strong momentum in Europe, particularly with the TOUCH prosthesis.

• Integration of KeriMedical and NeoOrtho strengthens the value segment, especially in Latin America, with new production facilities and market launches in Mexico, Argentina, and consolidated operations in Brazil.

• Production footprint expanded to six facilities, including new sites in Brazil, Belgium, and France, supporting scalability and regionalization.

• Commitment to Basel as headquarters, with ongoing facility expansion and long-term presence secured.

Financial Performance and Guidance

• Organic growth guidance for 2024 remains at 16%-18%, with high teens EBITDA margin targeted and net sales projected to reach CHF 269.3m in 2026.

• U.S. TOUCH business expected to reach profitability in 2025, leveraging existing distribution and specialist teams.

• May 2024 marked the first month with over 150 TOUCH implants sold in the U.S., supporting the 1,200 annual target.

• 90% of U.S. TOUCH cases are currently approved by payers, with a dedicated team managing reimbursement processes.

Product Innovation and Roadmap

• Robust R&D pipeline includes new launches like the NX Nail, AnkleFusion, Titan Nail, and personalized implants via 3D printing, with a comprehensive roadmap through 2029.

• Emphasis on simplifying procedures, reducing surgical time, and improving patient outcomes with innovations like the TOUCH prosthesis.

• Building an ecosystem around key products, including AI-powered surgical planning and patient-specific solutions.